N1BI34 Stock Price and Chart — BMFBOVESPA:N1BI34

Overview

Financials News Ideas Discussions Technicals Seasonals

Key facts today

RBC Capital upgraded Neurocrine Biosciences, Inc. (NBIX) to 'outperform' with a price target of $137. Needham also upgraded NBIX to 'Buy' with a target of $138.

Analyze the impact Analyze the impact

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.